No Data
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target
Sangamo Therapeutics Says Phase 1/2 Fabry Disease Study Showed Favorable Safety Profile; Shares Up Pre-Bell
Sangamo Therapeutics Announces Topline Results From Registrational Phase 1/2 STAAR Of ST-920 In Fabry Disease; Intends To Submit Biologics License Application In 2026
Express News | Sangamo Therapeutics Inc - STAAR Study Shows Positive Mean Annualized Egfr Slope at 52 Weeks
Express News | Sangamo Therapeutics Inc - Isaralgagene Civaparvovec Shows Favorable Safety and Tolerability Profile